Press release
Mucopolysaccharidosis Treatment Market Outlook 2025 to 2035 Growth Insights by Sangamo Therapeutics, Inc., REGENXBIO Inc., Orchard Therapeutics Limited
Mucopolysaccharidosis Treatment Market
Click Here for More Information:- https://www.futuremarketinsights.com/reports/mucopolysaccharidosis-treatment-market
Key Growth Drivers and Innovations
Advancements in biotechnology, improved diagnostic techniques facilitating early detection, and increased awareness of rare diseases are significantly boosting treatment adoption. The availability of ERT and ongoing research into curative gene therapies enhance treatment outcomes and patient quality of life. Pharmaceutical manufacturers are also collaborating with healthcare institutions to address unmet patient needs, further propelling market expansion.
Prevalence, Screening, and Treatment Uptake
MPS exhibits a global birth prevalence of approximately 1.56 per 100,000 live births, with MPS II often showing the highest subtype prevalence in many regions. While diagnostic delays persist, time to first treatment is improving in countries like the UK. For MPS I (Hurler), HSCT is the standard for children under 2-2.5 years, while ERT remains the default for other subtypes, with uptake defining coverage trends.
Market Performance and Half-Year Trends
The global MPS treatment market recorded a 5.2% CAGR from 2020 to 2024, with sales reaching USD 2,669.1 million in 2024. For 2025 to 2035, the market is predicted to grow at a 5.9% CAGR. Semi-annual projections show the H1 (2025-2035) CAGR at 5.9%, slightly decreasing to 5.4% in H2, reflecting minor shifts in market performance.
Strategic Growth Initiatives
Increased R&D investment by pharmaceutical companies is driving the development of more effective and targeted treatments, including advanced ERTs and potential gene therapies aiming for cures. For instance, REGENXBIO Inc. announced positive Phase III trial results for RGX-121 for MPS II in February 2024. Strategic acquisitions, like Kyowa Kirin Co., Ltd.'s acquisition of Orchard Therapeutics plc in January 2024, are expanding drug pipelines. Companies are also exploring combination therapies that target multiple disease facets, potentially offering more comprehensive and curative solutions, enhancing product uniqueness and market leadership.
Overcoming Cost Barriers
High treatment costs pose a significant challenge to MPS treatment adoption and market growth. ERT, gene therapies, and stem cell transplants are often expensive, creating financial burdens for patients and healthcare systems. These high costs limit patient access, especially in low- and middle-income countries, and can deter healthcare providers and insurers from widespread adoption, thus impacting early diagnosis and treatment.
Get Sample Report: - https://www.futuremarketinsights.com/reports/sample/rep-gb-5880
Competitive Tier Analysis
The MPS treatment market features a stratified competitive landscape. Tier 1 companies, including BioMarin Pharmaceutical, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Sumitomo Pharma Co., Ltd., command 68.6% of the global market with extensive product portfolios and broad geographical reach. Tier 2 companies, such as Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Sangamo Therapeutics, Inc., and JCR Pharmaceuticals, hold a 26.6% market share, demonstrating strong regional presence. Tier 3 companies act as specialized suppliers. Recent developments include JCR Pharmaceuticals and MEDIPAL HOLDINGS CORPORATION's Phase I/II clinical trial for JR-446 for MPS IIIB in December 2024, and JCR's co-promotion agreement with Sumitomo Pharma for IZCARGO in April 2023.
Key Regional Market Trends
The United States (7.4% CAGR) leads North America, driven by the FDA's focus on orphan drug designations, providing incentives for pharmaceutical companies to accelerate innovative therapies. Japan (6.3% CAGR) emphasizes new product launches, with manufacturers like Ultragenyx Pharmaceutical Inc. introducing new drugs for conditions such as MPS VII (e.g., in September 2022), improving patient outcomes and fostering innovation. The UK (5.4% CAGR) benefits from strategic collaborations between research institutes and hospitals, such as The University of Manchester's clinical trial for AVR-RD-05 for neuronopathic MPS II, which accelerates new treatment development and ensures faster market access. Other significant growth is observed in Germany (7.1% CAGR), China (4.1% CAGR), India (3.7% CAGR), and Australia (5.2% CAGR).
Discover Related Research:-
Vaginitis Treatment Drug Market
https://www.futuremarketinsights.com/reports/vaginitis-treatment-drugs-market
Atherosclerosis Market
https://www.futuremarketinsights.com/reports/atherosclerosis-market
Mucopolysaccharidosis Treatment Market
https://www.futuremarketinsights.com/reports/mucopolysaccharidosis-treatment-market
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analystsworldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mucopolysaccharidosis Treatment Market Outlook 2025 to 2035 Growth Insights by Sangamo Therapeutics, Inc., REGENXBIO Inc., Orchard Therapeutics Limited here
News-ID: 4123899 • Views: …
More Releases from Future Market Insights Inc
Global Eco-Friendly Webbing Market Outlook 2026-2036: Strategic Trends, Innovati …
The global Eco-Friendly Webbing Market is emerging as a pivotal force in sustainable industrial textiles, with the sector's total value forecast to climb from USD 650.1 million in 2025 to approximately USD 980.9 million by 2035, reflecting robust growth and expanding adoption across automotive, outdoor and safety applications. This projected expansion underscores escalating demand for recycled and environmentally responsible webbing materials that combine performance with reduced ecological footprint. The forecasted…
Universal Column Formwork Market Report 2026-2036: High-Value Insights for Strat …
The global Universal Column Formwork Market is on a strong upward trajectory, with total valuation expected to rise from approximately USD 586.3 million in 2025 to an estimated USD 1,011 million by 2035, reflecting a robust compound annual growth rate (CAGR) of 5.6% over the forecast period. This growth is firmly rooted in accelerating construction activities worldwide - from high-rise commercial towers to expansive infrastructure programs - as developers increasingly…
Comprehensive Analysis of the Beryllium Copper for Consumer Electronics Market: …
The global Beryllium Copper for Consumer Electronics Market is projected to expand steadily from an estimated USD 59.7 million in 2025 to USD 60.9 million by 2035, driven by sustained demand for high-performance materials in next-generation consumer devices and miniaturized electronic components. With a compound annual growth rate (CAGR) of 0.2%, this market demonstrates long-term stability in a mature yet technologically critical segment of the electronics materials landscape, signaling a…
Global Beryllium Copper for Telecommunication Market Deep-Dive 2026-2036: Strate …
The global beryllium copper for telecommunication market is valued at approximately US$ 420 million in 2024 and is projected to grow steadily through 2034, supported by rapid deployment of 5G infrastructure, rising data traffic, and the growing need for high-performance connectivity components. As telecom networks evolve toward higher frequencies and lower latency, beryllium copper continues to gain preference for its exceptional electrical conductivity, mechanical strength, fatigue resistance, and thermal stability,…
More Releases for MPS
Mucopolysaccharidosis I (MPS I) Market Emerging Trends and Growth Prospects 2034
Introduction
Mucopolysaccharidosis I (MPS I) is a rare lysosomal storage disorder caused by the deficiency of the enzyme α-L-iduronidase, leading to progressive multisystemic complications including skeletal deformities, organ dysfunction, and neurological decline in severe cases. The disease is categorized into Hurler, Hurler-Scheie, and Scheie syndromes, each varying in severity.
Over the past two decades, the availability of enzyme replacement therapy (ERT) has significantly improved patient outcomes, while hematopoietic stem cell transplantation (HSCT)…
Modular Panelboard System (MPS) Market 2022 | Detailed Report
Global Modular Panelboard System (MPS) Market 2021-2027, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. An exclusive data offered in this report is collected by research and industry experts team.
Download FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5256552
The report…
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Therapeutics - Pipelin …
Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a progressive disorder that primarily affects brain and spinal cord (central nervous system). People with MPS III generally do not display features at birth, but they begin to show signs and symptoms of this disorder during early childhood. Affected children often initially have delayed speech and behaviour problems.
Download the sample report @ https://www.pharmaproff.com/request-sample/1146
In later stages of this disorder, people…
Managed Print Services (MPS) Market Experience A Tremendous growth in future
HTF MI recently introduced Global Managed Print Services (MPS) Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Xerox Corporation, HP, Canon, Ricoh, Lexmark, Konica Minolta Inc.,…
ROTOCONTROL Appoints MPS Systems UK as Agent in United Kingdom
Trittau, Germany (July 18, 2013) – ROTOCONTROL, a manufacturer of leading-edge slitter/rewinder inspection machines today announced the appointment of MPS Systems UK as the ROTOCONTROL/LeoMat agent in the United Kingdom. MPS Systems UK, a subsidiary of the Dutch MPS Systems B.V., will now offer the ROTOCONTROL/LeoMat brand of leading-edge finishing machines for inspection, slitting, rewinding, die cutting, overprinting, digital labels and booklet labels for converters throughout the United Kingdom.
Led by…
Data8 to offer unlimited TPS, CTPS and MPS screening licences
Data8, the premier data enrichment specialist, have today announced that they will offer unlimited licenses to large volume TPS (Telephone Preference Service), CTPS (Corporate Telephone Preference Service) and MPS (Mail Preference Service) users. By removing the royalty fee structure, data8 believe it will encourage wide spread adoption by clients of these data files.
Antony Allen, managing director data8, “I am pleased to announce today that from 1st February 2012 we…
